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Available online at www.sciencedirect.comPersistent viral infections, inflammatory syndromes and ageing
all induce the accumulation of highly differentiated CD45RA re-
expressing memory T cells. These cells increase during ageing,
especially in individuals who are infected with cytomegalovirus
(CMV). These cells have decreased proliferative capacity,
increased activation of senescence signalling pathways and
greater susceptibility to apoptosis in vitro. However these cells
are capable of multiple effector functions and thus bear all the
hallmarks of short-lived effector T cells. This indicates that
senescence signalling may govern the unique characteristics of
effector T cells. In this article, we address the functional and
migratory properties of these T cells and mechanisms that are
involved in their generation. Finally we assess the potential for
manipulation of their activity and whether this may improve
immune function during ageing.
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Introduction
CD45, the leukocyte common antigen is a glycoprotein
that constitutes much of the cell surface of lymphocytes
[1,2]. Multiple isoforms of this molecule have been ident-
ified and these are differentially expressed depending on
cell type and activation status [2]. The large cytoplasmic
domain of this molecule has protein tyrosine phosphatase
activity [3]. The different CD45 isoforms are generated by
alternate splicing [4] from exons 4, 5 and 6, generating
CD45RA, RB and RC respectively [2]. It is now recognized
that naive T lymphocytes express the high molecular
weight isoform containing the A exon (CD45RA) and that
is lost after activation and replaced by the low molecular
weight isoform CD45RO [5]. Therefore CD45RA expres-
sing T cells were initially considered to be naı¨ve T cells
Open access under CC BY license.Current Opinion in Immunology 2012, 24:476–481 that were the precursors of CD45RO+ T cells that con-
tained the primed/memory T cell pool [5]. However the
division of T cells into CD45RA+ naı¨ve and CD45RO+
memory T cells was found to be an oversimplification, as
human T cells can revert from CD45RO+ to CD45RA+ in
vivo [6–8], and in vitro [9,10].
Highly differentiated CD45RA re-expressing T cells
within both the CD4 and CD8 compartments increase
considerably during ageing and after CMV infection [11–
14]. Numerous reports have suggested that these cells
have characteristics of end stage differentiation [15–17].
However more recent studies have shown that they can
be reactivated to proliferate when provided with appro-
priate co-stimulatory signals [18,19,20]. In this article
we question the relevance of highly differentiated
CD45RA re-expressing T cells to immunity in general,
the signalling processes that may govern their end-stage
characteristics, and whether the functions of these cells
are altered during ageing.
Primed CD45RA re-expressing T cells have
end-stage characteristics
The process of repeated T cell stimulation that leads to
differentiation may also result in a loss of replicative
capacity as a consequence of telomere erosion and/or
unrepaired DNA damage [21,22]. Both processes engage
a complex set of proteins involved in DNA repair [23]. If
the perceived damaged DNA is not rectified, then growth
arrest mediated by active cell signalling ensues [21,22].
There are a number of similarities between the senes-
cence induced growth arrest in fibroblasts in and human T
cells. For example signalling through the mitogen-acti-
vated protein kinase p38 MAP kinase and p53 occurs and
the cyclin-dependent kinase inhibitors p16 and p21 [21]
are involved in both cell types. However differences in
senescence between these cells include the fact that
senescent fibroblasts are viable but non-proliferative
[24] whereas end stage T cells are highly susceptible
to apoptosis [13] but may persist in vivo in the presence of
appropriate survival signals [21]. Indeed, analysis of deut-
erated glucose uptake in proliferating T cells indicates
that CD45RA re-expressing memory CD8+ T cells in
older individuals persist owing to a reduced rate of cell
death and not accelerated proliferation in vivo [25].
Another difference is that fibroblasts do not upregulate
the enzyme telomerase, which can add-back telomeres
and compensate for telomere loss, whereas human T cells
are able to do so [26,27]. It has been shown that CD45RA
re-expressing T cells lose the ability to induce thiswww.sciencedirect.com
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Migratory potential of CD45RA re-expressing T cells. The migratory
marker expression of human CD45RA re-expressing T cells indicates
their propensity for peripheral and inflamed tissues and not the lymph
nodes. However human CD45RA re-expressing T cells are not strictly
exiles from lymphoid organs as large amount of these cells are also
found in the bone marrow and spleen.enzyme and this contributes to their senescence
[20,28,29].
T cell differentiation can be defined using the relative
levels of expression of CD27, CD28 and CD45RA
[17,21,30,31], with highly differentiated end-stage T cells
being CD45RA+CD27CD28. These end-stage T cells
also express increased surface inhibitory receptors such as
KLRG1 [19] and CD57 [17,21,30,31]. CD45RA+
CD27CD28 T cells within both the CD4 and CD8
compartments also exhibit an increase in DNA damage
visualized by phosphorylated H2AX (gH2AX), a member
of the histone H2A family that is phosphorylated in
response to double-strand breaks [23]. In addition,
highly differentiated human T cells within both CD4
and CD8 compartments have altered signalling pathways
including defective Akt (PKB) ser473 phosphorylation
[13,29] and increased p38 MAP kinase signalling [20]
and both these alterations may contribute to the defective
telomerase activity in these cells [20,29].
The loss of telomeric repeats is another way of assessing
T cell differentiation [26] and initial studies indicated
that highly differentiated CD8+ T cells that re-express
CD45RA had the shortest telomeres [31,32]. However
studies using larger numbers of donors showed that
CD45RA+CD27 T cells have relatively long telomeres
compared to the CD45RACD27 effector memory T
cells but shorter telomeres than naı¨ve and central memory
populations in both CD4+ and CD8+ compartments
[20,28]. Therefore CD45RA+ re-expressing T cells have
multiple signatures of senescence and end-stage differ-
entiation however these characteristics are not totally
dependent on telomere erosion [21].
Primed CD45RA re-expressing T cells are a
potent effector population
It has been shown that primed CD4 and CD8 T cells that
re-express CD45RA can secrete multiple cytokines in-
cluding IFN-g and TNF-a and exhibit potent cytotoxic
activity after activation [9,13,16]. However these cells
have reduced capacity to secrete IL-2 [30,32]. This has
been demonstrated for total T cells as well as populations
that are specific for Epstein Barr virus [33] as well as
cytomegalovirus [11,12,34]. Although these cells accumu-
late in older humans [11,13,14] it is not clear if these cells
are fully functional since some reports show that CMV
specific T cells have reduced capacity to synthesize IFN-
g [35]. The majority of studies of CD45RA re-expressing
T cells have been performed with peripheral blood popu-
lations. However an important observation is that
although these cells have poor proliferative activity they
can be activated and proliferate if provided with appro-
priate co-stimulatory signals or accessory populations
[9,29]. Once activated, these cells can mediate potent
effector function but die rapidly [13]. This cell population
may therefore have a role as a sentinel population ofwww.sciencedirect.com effector cells that patrol sites of frequent antigenic
encounter. However the effector properties of these cells
suggest that they may have a role in other tissues and it is
therefore important to assess their migratory potential.
Migratory potential of CD45RA re-expressing
T cells
The effectiveness of a T cell is closely related to its
propensity to migrate to particular organs and tissues
[36,37]. Naı¨ve and central memory cells have a propensity
to home to draining lymph nodes (LN) where dendritic
cells can present cognate antigen from the site of infection
[36–38] while effector memory cells require entry into
peripheral tissues where they induce pathogen clearance
through cytokine secretion and cytotoxic activity [36].
The chemokine receptors CXCR4, CCR7 and CD62L
that are expressed by naı¨ve and central memory T cells
facilitate their migration into LNs [37,39]. CD45RA re-
expressing memory T cells do not express these four
homing receptors that strongly suggest an inability of the
population to migrate into LN (Figure 1). Indeed, cyto-
megalovirus (CMV)-specific CD8+ T cells that express
CD45RA are absent from the LN of humans despite
being present at high percentages in the peripheral blood
[40]. Instead, CD45RA re-expressing memory T cells
constitutively express receptors that direct their
migration to peripheral and/or inflamed tissue. These
include high levels of CX3CR1, which binds fraktalkineCurrent Opinion in Immunology 2012, 24:476–481
478 Immune senescencethat is expressed by stressed endothelium, thus allowing
entry into inflamed vascular endothelium [41]; high levels
of CD11a or CD18, the components of LFA-1 that
facilitates recruitment to infection sites by binding
ICAM-1; and CD49e that allows interaction with extra-
cellular matrix [42]. Upon stimulation with cognate
antigen, CD45RA re-expressing memory T cells also
upregulate other inflammation associated adhesion mar-
kers, such as CCR5 that binds RANTES or macrophage
inflammatory proteins (MIP) that are both expressed by
inflamed tissue [12]. CD45RA re-expressing memory T
cells are also found in human spleen and bone marrow
(BM) [13,43,44,45].
Collectively the available data suggest that although
CD45A re-expressing T cells are highly differentiated,
close to senescence and have low proliferative capacity,
they migrate preferentially to sites of inflammation where
they may exert their potent effector activity [42]. How-
ever it is also possible that the spleen and bone marrow may
be sites where these cells are generated (Figure 1) [13].
CD45RA re-expressing T cells may
accumulate via antigen-independent cytokine
driven homeostasis
Memory T cells are maintained by and can differentiate
in response to both antigen activation and homeostatic
cytokine stimulation [36]. It is unlikely that CD45RA re-
expressing memory cells have experienced a recent
encounter with antigen since TCR ligation induces
CD45RO expression both in vitro and during primary
responses in vivo [12,15,46,47]. However after resol-
ution of a primary infection with Epstein-Barr virus
(EBV) some antigen specific T cells express CD45RA
[8]. In addition, CD45RA+ re-expressing CD8+ T cells
were found to be the dominant (quiescent) memory
population that was generated following vaccination
against yellow fever despite the fact that these cells were
CD45RO+ initially [47]. This highlights that CD45RA
re-expressing memory cells may arise without the
requirement of repeated antigen exposure, since these
individuals were only vaccinated once, and can survive in
vivo in the absence of antigen [47].
It has been shown that CD45RA re-expressing memory
cells can be generated from the CD45RO population of T
cells by the addition of the homeostatic cytokines IL-7
and IL-15, in the absence of antigen in vitro [9,10,13,15].
Isolated EBV-specific CD8+ T cells that were CD45RO+
could be induced to re-express CD45RA by incubation
with IL-15, and these cells exhibited potent cytotoxic
activity against EBV infected target cells [9]. Further-
more, IL-15 injections can induce massive expansions of
CCR7CD28CD8+ memory T cells in rhesus macaques
[48] however it is not clear if these cells are equivalent to
the CD45RA re-expressing T cells in humans as reagents
to this molecule is not available in these primates. ItCurrent Opinion in Immunology 2012, 24:476–481 would therefore be predicted that these cells may be
generated in tissues that contain large amounts of homeo-
static cytokines or cytokine producing cells [49,50]. This
is supported by the observation that CD4+
CD45RA+CD27T cells of different antigen specificities
were found at significantly higher proportions in the bone
marrow, a recognized site of IL-7 production [51], com-
pared to the blood of the same individuals [13]. Finally,
the fact that IL-15 stimulation can maintain human
memory cells without telomere erosion in vitro may
explain how CD8+CD45RA re-expressing memory cells
become highly differentiated without chronic reduction
in telomere length in vivo [52], since these cytokines can
induce telomerase activity [52,53]. Important but unan-
swered questions are whether these cytokines engage
senescence signalling pathways in the cells that re-
express CD45RA and whether the CD45RA molecule
itself is essential for the function of these cells. Further-
more since large populations of CD45RA re-expressing T
cells dominate the T cell compartment of older humans,
the role of homeostatic proliferation in shaping the T cell
repertoire during ageing has to be addressed.
Can T cell senescence be reversed?
The data that have been discussed above indicates that
CD45RA re-expressing T cells exhibit characteristics of
senescence. However, these characteristics of senescence
are maintained by multiple distinct signalling processes
and some of these changes are reversible. For example, as
T cells differentiate they lose the expression of the sur-
face co-stimulatory molecule CD28, which may result in
some of the functional changes in highly differentiated
populations [27,54]. However, the induction of CD28 re-
expression or the ligation of alternative co-stimulatory
molecules such as ICOS, CD137 and CD134, enhance the
proliferation [18,29] in certain subsets of CD8+CD28T
cells [29]. Highly differentiated T cells also express
multiple inhibitory receptors [55]. The defective prolifer-
ation of these cells can be reversed by blockade of
KLRG1 and PD-1 signalling, which induces AKT
Ser473 phosphorylation that is defective in these cells
[19,56]. However, neither the blockade of KLRG1 or
PD-1 signalling reverses the telomerase defect in these
cells [19,56].
By contrast, it has been shown that CD45RA re-expres-
sing CD4+ T cells have increased expression of both total
and phosphorylated forms of p38 MAP kinase, that is
involved in the senescence process in fibroblasts
[57,58]. The inhibition of p38 signalling using a specific
inhibitor in CD45RA+CD27CD4+ T cells significantly
enhanced the proliferation, telomerase activity and sur-
vival of these cells after TCR activation [20]. Similar
observations have also been made in CD8+
CD45RA+CD27 T cells (Henson and Akbar, unpub-
lished observations). An additional way to reverse senes-
cence in human T cells is by transducing these cells withwww.sciencedirect.com
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Potential routes for functional manipulation of CD45RA re-expressing T cells. CD45RA re-expressing T cells display both proliferative and signalling
defects but remain highly polyfunctional, is it therefore possible to enhance immunity by boosting the function of CD45RA re-expressing T cells.
Potential avenues for manipulating function include replacing lost co-stimulatory molecules, such as CD28 or TNF family members or blocking
inhibitory receptor signalling. Intervention may be targeted at either the prevention of CMV replication by vaccination or anti-viral therapy or the
removal of CMV-specific cells. Finally DNA damage response could be manipulated, such as blockade of p53 or p38 MAPK signalling.hTERT, the catalytic component of telomerase and
many laboratories have achieved this goal [59]. Alterna-
tively, the activity of this enzyme can be enhanced using
ERK kinase activators [60].
Although there are ways available to reverse T cell senes-
cence the key questions that arise are whether senescence
restricts immune function in older humans in the first place
and second whether it is safe to do so. Highly differentiated
CD45RA re-expressing T cells have been shown to
accumulate in older adults [27,28] patients with persistent
viral infections [11,16,61] and those with inflammatory
syndromes such as rheumatoid arthritis [42,62]. As T cell
function is reduced in patients with chronic viral infections
and in older adults [35], it raises the possibility that
enhancement of function of the CD45RA re-expressing
population may boost immunity (Figure 2). However the
reversal of senescence by enhancing telomerase by a
variety of ways has risks, since senescence-induced pro-
liferative arrest is considered to be a first line of defence
against cancer [22] and blocking this proliferative check-
point may pose the risk of propagating T cells with DNA
damage and thus malignancy. In addition reversal of the
proliferative defect in T cells by blocking p38 may lead to
decreased rather than increased effector functions as this
molecule is important for pro-inflammatory cytokine
secretion [20,63]. Ideally, the enhancement of immunity
during ageing would require a strategy that enhances the
function of T cells with minimal risk of malignancy or
inflammation. Although progress has been made about
how T cell function is constrained during differentiation
and ageing, the current state of expertise is somewhat shortwww.sciencedirect.com of this goal. Nevertheless since the proliferation of T cells
can be enhanced temporarily by p38 inhibition or by
blocking inhibitory receptors, this may be a way to boost
specific T cell populations intermittently, for example
during vaccination.
Conclusions
CD45RA re-expressing memory T cells display senes-
cence-related proliferative defects that are reversible. In
young individuals these cells are capable of efficient
cytokine secretion and cytotoxicity however it is not
completely clear if these cells lose effector function
during ageing. The CD45RA re-expressing T cells have
relatively long telomeres, suggesting that these cells are
governed by telomere-independent senescence. The
temporary reversal of proliferative defects in highly dif-
ferentiated T cells may be a way to increase specific T cell
numbers during vaccination, but long term reversal of
senescence carries the risk of malignancy.
Acknowledgements
This work was supported by the Biotechnology and Biological Sciences
Research Council.
References and recommended reading
Papers of particular interest, published within the period of review,
have been highlighted as:
 of special interest
 of outstanding interest
1. Fabre JW, Williams AF: Quantitative serological analysis of a
rabbit anti-rat lymphocyte serum and preliminary biochemical
characterisation of the major antigen recognised.
Transplantation 1977, 23:349-359.Current Opinion in Immunology 2012, 24:476–481
480 Immune senescence2. Thomas ML: The leukocyte common antigen family. Annu Rev
Immunol 1989, 7:339-369.
3. Charbonneau H, Tonks NK, Walsh KA, Fischer EH: The leukocyte
common antigen (CD45): a putative receptor-linked protein
tyrosine phosphatase. Proc Natl Acad Sci USA 1988,
85:7182-7186.
4. Barclay AN, McCall MN: CD45; from alloantigen to mapping of
restricted epitopes using recombinant soluble CD45 isoforms.
Biochem Soc Trans 1992, 20:161-164.
5. Akbar AN, Terry L, Timms A, Beverley PC, Janossy G: Loss of
CD45R and gain of UCHL1 reactivity is a feature of primed T
cells. J Immunol 1988, 140:2171-2178.
6. Michie CA, McLean A, Alcock C, Beverley PC: Lifespan of human
lymphocyte subsets defined by CD45 isoforms. Nature 1992,
360:264-265.
7. Wills MR, Carmichael AJ, Weekes MP, Mynard K, Okecha G,
Hicks R, Sissons JG: Human virus-specific CD8+ CTL clones
revert from CD45ROhigh to CD45RAhigh in vivo:
CD45RAhighCD8+ T cells comprise both naive and memory
cells. J Immunol 1999, 162:7080-7087.
8. Callan MF, Tan L, Annels N, Ogg GS, Wilson JD, O’Callaghan CA,
Steven N, McMichael AJ, Rickinson AB: Direct visualization of
antigen-specific CD8+ T cells during the primary immune
response to Epstein-Barr virus In vivo. J Exp Med 1998,
187:1395-1402.
9. Dunne PJ, Belaramani L, Fletcher JM, Fernandez de Mattos S,
Lawrenz M, Soares MV, Rustin MH, Lam EW, Salmon M,
Akbar AN: Quiescence and functional reprogramming of
Epstein-Barr virus (EBV)-specific CD8+ T cells during
persistent infection. Blood 2005, 106:558-565.
10. Geginat J, Sallusto F, Lanzavecchia A: Cytokine-driven
proliferation and differentiation of human naive, central
memory, and effector memory CD4(+) T cells. J Exp Med 2001,
194:1711-1719.
11. Khan N, Shariff N, Cobbold M, Bruton R, Ainsworth JA, Sinclair AJ,
Nayak L, Moss PA: Cytomegalovirus seropositivity drives the
CD8 T cell repertoire toward greater clonality in healthy elderly
individuals. J Immunol 2002, 169:1984-1992.
12. Wills MR, Okecha G, Weekes MP, Gandhi MK, Sissons PJ,
Carmichael AJ: Identification of naive or antigen-experienced
human CD8(+) T cells by expression of costimulation and
chemokine receptors: analysis of the human
cytomegalovirus-specific CD8(+) T cell response. J Immunol
2002, 168:5455-5464.
13. Libri V, Azevedo RI, Jackson SE, Di Mitri D, Lachmann R,
Fuhrmann S, Vukmanovic-Stejic M, Yong K, Battistini L, Kern F
et al.: Cytomegalovirus infection induces the accumulation of
short-lived, multifunctional CD4(+) CD45RA(+) CD27(S) T
cells: the potential involvement of interleukin-7 in this process.
Immunology 2011, 132:326-339.
14. Derhovanessian E, Maier AB, Hahnel K, Beck R, de Craen AJ,
Slagboom EP, Westendorp RG, Pawelec G: Infection with
cytomegalovirus but not herpes simplex virus induces the
accumulation of late-differentiated CD4+ and CD8+ T-cells in
humans. J Gen Virol 2011, 92:2746-2756.
15. Geginat J, Lanzavecchia A, Sallusto F: Proliferation and
differentiation potential of human CD8+ memory T-cell
subsets in response to antigen or homeostatic cytokines.
Blood 2003, 101:4260-4266.
16. Appay V, Dunbar PR, Callan M, Klenerman P, Gillespie GM,
Papagno L, Ogg GS, King A, Lechner F, Spina CA et al.: Memory
CD8+ T cells vary in differentiation phenotype in different
persistent virus infections. Nat Med 2002, 8:379-385.
17. Koch S, Larbi A, Derhovanessian E, Ozcelik D, Naumova E,
Pawelec G: Multiparameter flow cytometric analysis of CD4
and CD8 T cell subsets in young and old people. Immun Ageing
2008, 5:6.
18.

Waller EC, McKinney N, Hicks R, Carmichael AJ, Sissons JG,
Wills MR: Differential costimulation through CD137 (4-1BB)
restores proliferation of human virus-specific ‘‘effectorCurrent Opinion in Immunology 2012, 24:476–481 memory’’ (CD28(-) CD45RA(HI)) CD8(+) T cells. Blood 2007,
110:4360-4366.
This study shows that CD45RA re-expressing T cells are not terminally
differentiated but require CD137L in order to proliferate.
19.

Henson SM, Franzese O, Macaulay R, Libri V, Azevedo RI, Kiani-
Alikhan S, Plunkett FJ, Masters JE, Jackson S, Griffiths SJ et al.:
KLRG1 signaling induces defective Akt (ser473)
phosphorylation and proliferative dysfunction of highly
differentiated CD8+ T cells. Blood 2009, 113:6619-6628.
This article demonstrates that the proliferative defect in highly differen-
tiated CD8+ T cells is actively maintained by KLRG1 signalling.
20.

Di Mitri D, Azevedo RI, Henson SM, Libri V, Riddell NE,
Macaulay R, Kipling D, Soares MV, Battistini L, Akbar AN:
Reversible senescence in human CD4+CD45RA+CD27S
memory T cells. J Immunol 2011, 187:2093-2100.
This recent article shows that CD4+ CD45RA re-expressing T cells display
features of telomere-independent senescence that are reversibly regu-
lated by the p38 MAPK pathway.
21. Akbar AN, Henson SM: Are senescence and exhaustion
intertwined or unrelated processes that compromise
immunity? Nat Rev Immunol 2011, 11:289-295.
22. Campisi J: Senescent cells, tumor suppression, and
organismal aging: good citizens, bad neighbors. Cell 2005,
120:513-522.
23.

d’Adda di Fagagna F, Reaper PM, Clay-Farrace L, Fiegler H,
Carr P, Von Zglinicki T, Saretzki G, Carter NP, Jackson SP: A DNA
damage checkpoint response in telomere-initiated
senescence. Nature 2003, 426:194-198.
This paper shows that inactivation of DNA damage checkpoint kinases,
53BP1, MDC1 and NBS, in senescent cells can restore cell-cycle pro-
gression into S phase.
24. Faragher RG, Kipling D: How might replicative senescence
contribute to human ageing? Bioessays 1998, 20:985-991.
25. Wallace DL, Masters JE, De Lara CM, Henson SM, Worth A,
Zhang Y, Kumar SR, Beverley PC, Akbar AN, Macallan DC: Human
cytomegalovirus-specific CD8(+) T-cell expansions contain
long-lived cells that retain functional capacity in both young
and elderly subjects. Immunology 2011, 132:27-38.
26. Weng NP, Levine BL, June CH, Hodes RJ: Regulated expression
of telomerase activity in human T lymphocyte development
and activation. J Exp Med 1996, 183:2471-2479.
27. Effros RB: Replicative senescence of CD8 T cells: effect on
human ageing. Exp Gerontol 2004, 39:517-524.
28. Plunkett FJ, Franzese O, Belaramani LL, Fletcher JM, Gilmour KC,
Sharifi R, Khan N, Hislop AD, Cara A, Salmon M et al.: The impact
of telomere erosion on memory CD8+ T cells in patients with
X-linked lymphoproliferative syndrome. Mech Ageing Dev
2005, 126:855-865.
29. Plunkett FJ, Franzese O, Finney HM, Fletcher JM, Belaramani LL,
Salmon M, Dokal I, Webster D, Lawson AD, Akbar AN: The loss of
telomerase activity in highly differentiated CD8+CD28-CD27S
T cells is associated with decreased Akt (Ser473)
phosphorylation. J Immunol 2007, 178:7710-7719.
30. Appay V, van Lier RA, Sallusto F, Roederer M: Phenotype and
function of human T lymphocyte subsets: consensus and
issues. Cytometry A 2008, 73:975-983.
31. Romero P, Zippelius A, Kurth I, Pittet MJ, Touvrey C, Iancu EM,
Corthesy P, Devevre E, Speiser DE, Rufer N: Four functionally
distinct populations of human effector-memory CD8+ T
lymphocytes. J Immunol 2007, 178:4112-4119.
32. Hamann D, Baars PA, Rep MH, Hooibrink B, Kerkhof-Garde SR,
Klein MR, van Lier RA: Phenotypic and functional separation of
memory and effector human CD8+ T cells. J Exp Med 1997,
186:1407-1418.
33. Hislop AD, Gudgeon NH, Callan MF, Fazou C, Hasegawa H,
Salmon M, Rickinson AB: EBV-specific CD8+ T cell memory:
relationships between epitope specificity, cell phenotype, and
immediate effector function. J Immunol 2001, 167:2019-2029.
34. Lachmann R, Bajwa M, Vita S, Smith H, Cheek E, Akbar A, Kern F:
Polyfunctional T cells accumulate in large humanwww.sciencedirect.com
Properties of end-stage human T cells Henson, Riddell and Akbar 481cytomegalovirus-specific T cell responses. J Virol 2012,
86:1001-1009.
35. Ouyang Q, Wagner WM, Voehringer D, Wikby A, Klatt T, Walter S,
Muller CA, Pircher H, Pawelec G: Age-associated accumulation
of CMV-specific CD8+ T cells expressing the inhibitory killer
cell lectin-like receptor G1 (KLRG1). Exp Gerontol 2003,
38:911-920.
36. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A: Two
subsets of memory T lymphocytes with distinct homing
potentials and effector functions. Nature 1999, 401:708-712.
37. von Andrian UH, Mackay CR: T-cell function and migration. Two
sides of the same coin. N Engl J Med 2000, 343:1020-1034.
38. Pittet MJ, Mempel TR: Regulation of T-cell migration and
effector functions: insights from in vivo imaging studies.
Immunol Rev 2008, 221:107-129.
39. Miyasaka M, Tanaka T: Lymphocyte trafficking across high
endothelial venules: dogmas and enigmas. Nat Rev Immunol
2004, 4:360-370.
40.

Remmerswaal EB, Havenith SH, Idu MM, van Leeuwen EM, van
Donselaar KA, Ten Brinke A, van der Bom-Baylon N,
Bemelman FJ, van Lier RA, Ten Berge IJ: Human virus-specific
effector-type T cells accumulate in blood but not in lymph
nodes. Blood 2012, 119:1702-1712.
This study uses paired human LN and blood samples showing that CMV-
specific CD8+ T cells are not present in the LNs and do not limit
immunologic space at sites where immune reactions are initiated. Thus
arguing against the possibility of memory cell attrition as a cause for low
responses to vaccination in the elderly.
41. Hertoghs KM, Moerland PD, van Stijn A, Remmerswaal EB,
Yong SL, van de Berg PJ, van Ham SM, Baas F, ten Berge IJ, van
Lier RA: Molecular profiling of cytomegalovirus-induced
human CD8+ T cell differentiation. J Clin Invest 2010,
120:4077-4090.
42.

Faint JM, Annels NE, Curnow SJ, Shields P, Pilling D, Hislop AD,
Wu L, Akbar AN, Buckley CD, Moss PA et al.: Memory T cells
constitute a subset of the human CD8+CD45RA+ pool with
distinct phenotypic and migratory characteristics. J Immunol
2001, 167:212-220.
This paper reveals the chemokine receptor profile and migratory potential
of CD45RA+ re-expressing T cells and shows that these cells are under-
represented in lymph nodes but make up all the CD8+CD45RA+ T cells in
peripheral tissues.
43. Langeveld M, Gamadia LE, ten Berge IJ: T-lymphocyte subset
distribution in human spleen. Eur J Clin Invest 2006, 36:250-256.
44. Palendira U, Chinn R, Raza W, Piper K, Pratt G, Machado L, Bell A,
Khan N, Hislop AD, Steyn R et al.: Selective accumulation of
virus-specific CD8+ T cells with unique homing phenotype
within the human bone marrow. Blood 2008, 112:3293-3302.
45.

Herndler-Brandstetter D, Landgraf K, Tzankov A, Jenewein B,
Brunauer R, Laschober GT, Parson W, Kloss F, Gassner R,
Lepperdinger G et al.: The impact of aging on memory T cell
phenotype and function in the human bone marrow. J Leukoc
Biol 2012, 91:197-205.
This study highlights the impact of ageing on T cells memory within the
human BM and shows that IL-15 producing cells are important for the
maintenance of polyfunctional T cells, which accumulate in high numbers
in the BM with age.
46. Dunne PJ, Faint JM, Gudgeon NH, Fletcher JM, Plunkett FJ,
Soares MV, Hislop AD, Annels NE, Rickinson AB, Salmon M et al.:
Epstein-Barr virus-specific CD8(+) T cells that re-express
CD45RA are apoptosis-resistant memory cells that retain
replicative potential. Blood 2002, 100:933-940.
47.

Akondy RS, Monson ND, Miller JD, Edupuganti S, Teuwen D,
Wu H, Quyyumi F, Garg S, Altman JD, Del Rio C et al.: The yellow
fever virus vaccine induces a broad and polyfunctional human
memory CD8+ T cell response. J Immunol 2009, 183:7919-7930.
This work demonstrates that CD45RA+ re-expressing CD8+ T cells werewww.sciencedirect.com found to be the major memory population generated following vaccina-
tion against yellow fever, highlighting that CD45RA re-expressing mem-
ory cells may arise without the requirement of repeated antigen exposure.
48. Sneller MC, Kopp WC, Engelke KJ, Yovandich JL, Creekmore SP,
Waldmann TA, Lane HC: IL-15 administered by continuous
infusion to rhesus macaques induces massive expansion of
CD8+ T effector memory population in peripheral blood. Blood
2011, 118:6845-6848.
49. Parretta E, Cassese G, Barba P, Santoni A, Guardiola J, Di Rosa F:
CD8 cell division maintaining cytotoxic memory occurs
predominantly in the bone marrow. J Immunol 2005,
174:7654-7664.
50. Herndler-Brandstetter D, Landgraf K, Jenewein B, Tzankov A,
Brunauer R, Brunner S, Parson W, Kloss F, Gassner R,
Lepperdinger G et al.: Human bone marrow hosts
polyfunctional memory CD4+ and CD8+ T cells with close
contact to IL-15-producing cells. J Immunol 2011,
186:6965-6971.
51. Sudo T, Ito M, Ogawa Y, Iizuka M, Kodama H, Kunisada T,
Hayashi S, Ogawa M, Sakai K, Nishikawa S: Interleukin 7
production and function in stromal cell-dependent B cell
development. J Exp Med 1989, 170:333-338.
52. Wallace DL, Berard M, Soares MV, Oldham J, Cook JE, Akbar AN,
Tough DF, Beverley PC: Prolonged exposure of naive CD8+ T
cells to interleukin-7 or interleukin-15 stimulates proliferation
without differentiation or loss of telomere length. Immunology
2006, 119:243-253.
53. Soares MV, Borthwick NJ, Maini MK, Janossy G, Salmon M,
Akbar AN: IL-7-dependent extrathymic expansion of CD45RA+
T cells enables preservation of a naive repertoire. J Immunol
1998, 161:5909-5917.
54. Weng NP, Akbar AN, Goronzy J: CD28(-) T cells: their role in the
age-associated decline of immune function. Trends Immunol
2009, 30:306-312.
55. Blackburn SD, Shin H, Haining WN, Zou T, Workman CJ, Polley A,
Betts MR, Freeman GJ, Vignali DA, Wherry EJ: Coregulation of
CD8+ T cell exhaustion by multiple inhibitory receptors during
chronic viral infection. Nat Immunol 2009, 10:29-37.
56. Henson SM, Macaulay R, Franzese O, Akbar AN: Reversal of
functional defects in highly differentiated young and old CD8 T
cells by PDL blockade. Immunology 2012, 135:355-363.
57. Davis T, Bachler MA, Wyllie FS, Bagley MC, Kipling D: Evaluating
the role of p38 MAP kinase in growth of Werner syndrome
fibroblasts. Ann N Y Acad Sci 2010, 1197:45-48.
58.

Passos JF, Nelson G, Wang C, Richter T, Simillion C, Proctor CJ,
Miwa S, Olijslagers S, Hallinan J, Wipat A et al.: Feedback
between p21 and reactive oxygen production is necessary for
cell senescence. Mol Syst Biol 2010, 6:347.
This paper highlights the existence of a dynamic feedback loop that locks
fibroblasts into an actively maintained state of cellular senescence. The
activation of p21 induces mitochondrial dysfunction and production of
ROS that in turn maintains an ongoing DDR.
59. Akbar AN, Vukmanovic-Stejic M: Telomerase in T lymphocytes:
use it and lose it? J Immunol 2007, 178:6689-6694.
60. Parish ST, Wu JE, Effros RB: Modulation of T lymphocyte
replicative senescence via TNF-{alpha} inhibition: role of
caspase-3. J Immunol 2009, 182:4237-4243.
61. Akbar AN, Fletcher JM: Memory T cell homeostasis and
senescence during aging. Curr Opin Immunol 2005, 17:480-485.
62. Goronzy JJ, Weyand CM: Rheumatoid arthritis. Immunol Rev
2005, 204:55-73.
63. Ono K, Han J: The p38 signal transduction pathway: activation
and function. Cell Signal 2000, 12:1-13.Current Opinion in Immunology 2012, 24:476–481
